Interestingly, published results demonstrated that the combination was associated with a good safety profile and a promising anti-tumor activity in melanoma patients with disease progression during previous anti-PD-1 therapy (anti-CTLA-4 therapy was allowed more than 3 months prior to study entry), and the overall toxicity profile was consistent with the profiles of each individual agent [133]. Here, PDCD1 is linked to melanoma.